U.S. Medical Adhesives Market Size, Share & Forecast 2026–2032

ID: MR-11126 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Medical Adhesives Market
  • ✓Market Size 2024: USD 5.2 billion
  • ✓Market Size 2032: USD 8.1 billion
  • ✓CAGR: 5.7%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Pass-Through Payment Cliff: Medicare device pass-through under 42 CFR 419.66 lasts two to three years for new adhesive-based devices. After expiry, Outpatient Prospective Payment System bundled rates absorb adhesive costs, squeezing suppliers such as Smith & Nephew.
FINDING 02
Tariffs Favor Domestic Converters: Analysts treat Commerce's Section 232 medical device investigation, opened September 2025, as a pure cost threat. Domestic converters in New Jersey and Massachusetts will gain share as group purchasing organizations prioritize U.S.-made sterile dressings.
ANALYST RECOMMENDATION

Analyst Recommendation — Lock Quality Systems Now: Adhesive OEMs should complete QMSR transition audits under 21 CFR Part 820 before February 2, 2026, and secure ISO 10993-1 biocompatibility files for every new chemistry. Gaps will delay 510(k) clearances and trigger FDA inspection findings.

Medical Adhesives in the United States: Market Overview

The U.S. medical adhesives market was valued at USD 5.2 billion in 2024 and is forecast to reach USD 8.1 billion by 2032. Demand concentrates in surgical wound closure, transdermal drug delivery, ostomy care, and device assembly, with hospitals and ambulatory surgical centers consuming the largest share of volume. Structure reflects multinational chemistry producers, medtech conglomerates, and converters supplying tapes, films, and hydrocolloid laminates. Private firms lead product development, while federal policy shapes reimbursement and clearance timing.

Government has been the dominant force in setting market boundaries rather than producing goods. FDA premarket pathways under the Federal Food, Drug, and Cosmetic Act determine which adhesive products reach hospitals, while CMS payment rules under the Social Security Act decide which procedures are reimbursed. Private players including 3M, Avery Dennison Medical, and Henkel have led innovation in pressure-sensitive and cyanoacrylate chemistries, shaping the technology mix more than any federal program.

Policy-Driven Growth in U.S. Medical Adhesives

Three federal mechanisms are pulling demand. First, the Hospital-Acquired Condition Reduction Program under Section 1886(q) of the Social Security Act cuts 1% of Medicare inpatient payments from hospitals in the worst-performing quartile for conditions including surgical site infections. Hospitals respond by favoring advanced incisional dressings and antimicrobial-adhesive closures, raising unit demand per procedure.

Second, Medicare device pass-through under 42 CFR 419.66 provides add-on payments for two to three years to new adhesive-based devices under the Hospital Outpatient Prospective Payment System. Third, the Medical Device User Fee Amendments under MDUFA V, authorized through fiscal year 2027, fund a 90-day FDA review goal for 510(k) submissions, shortening time to market for new sealants and tapes. Each mechanism converts clinical need into reimbursed, clearable product volume.

Regulatory Barriers and Compliance Costs

FDA's Center for Devices and Radiological Health administers premarket notification under Section 510(k) and the Quality Management System Regulation, which amends 21 CFR Part 820 to incorporate ISO 13485:2016 from February 2, 2026. A standard 510(k) user fee exceeded USD 24,000 in fiscal year 2025, and biocompatibility testing under ISO 10993-1 adds months and substantial cost for each new chemistry.

Commerce's Bureau of Industry and Security opened a Section 232 investigation in September 2025 covering medical devices and consumables, including adhesive dressings and tapes. Resulting tariffs would raise input costs for imported acrylic and silicone raw materials. EPA also requires Toxic Substances Control Act premanufacture notices for novel adhesive monomers, adding review time before commercial use.

Policy-Created Opportunities in the United States

The Centers for Medicare & Medicaid Services' Ambulatory Surgical Center Covered Procedures List expansion moves orthopedic and gynecologic procedures into outpatient settings. Each shift creates demand for closure adhesives and incision dressings sized for ASC workflows, where Medline Industries and Cardinal Health hold distribution scale.

Buy American Act provisions in Federal Acquisition Regulation Part 25 favor domestically converted sterile adhesive products in federal procurement, including Department of Veterans Affairs contracts. Converters with U.S. facilities in New Jersey and Massachusetts can capture these awards. Manufacturers should pursue VA Federal Supply Schedule listings to access this demand.

Market at a Glance

MetricDetail
Market Size 2024USD 5.2 billion
Market Size 2032USD 8.1 billion
Growth Rate (CAGR)5.7%
Most Critical Decision FactorFDA 510(k) clearance timing and reimbursement eligibility under CMS payment rules
Largest RegionNortheast (New Jersey, Massachusetts, Pennsylvania)
Competitive StructureConsolidated; multinational chemistry and medtech firms dominate

Leading Market Participants

  • 3M
  • Johnson & Johnson
  • Avery Dennison Medical
  • H.B. Fuller
  • Henkel
  • Bostik
  • Smith & Nephew
  • Medline Industries
  • Cardinal Health
  • Tredegar Corporation

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act, with device provisions added by the Medical Device Amendments of 1976 and fee-funded review timelines set under MDUFA V in the FDA Reauthorization Act of 2017. FDA's Center for Devices and Radiological Health enforces premarket clearance, unique device identification under 21 CFR Part 830, and labeling rules under 21 CFR Part 801. The QMSR takes effect February 2, 2026.

Compared with the European Union, where Regulation (EU) 2017/745 imposes notified-body certification with transition deadlines extending to 2027 and 2028, the U.S. 510(k) pathway is faster but relies on substantial equivalence. Japan's PMDA and Health Canada's Medical Devices Regulations (SOR/98-282) require separate local registrations. Upcoming changes include MDUFA VI negotiations ahead of the 2027 reauthorization and the pending Section 232 determination on medical device imports.

Long-Term Policy Outlook for U.S. Medical Adhesives

MDUFA VI must be enacted before the current program expires on September 30, 2027, and will set the 510(k) review clock for the following five years. FDA will extend digital submission and AI-assisted review tools, shortening clearance times for low-risk tape and dressing products by 2028.

Section 232 tariff outcomes will push sourcing toward domestic converters and USMCA-compliant suppliers in Mexico. Site-neutral payment policy for outpatient departments will move procedures into ASCs and physician offices, shifting adhesive volume toward single-use closures by 2032.

Frequently Asked Questions

Most adhesive tapes, dressings, and wound closure products are Class II devices cleared through 510(k) premarket notification under the Federal Food, Drug, and Cosmetic Act. Biologic sealants containing fibrin or thrombin follow biologics licensing or premarket approval instead.
The QMSR amends 21 CFR Part 820 to incorporate ISO 13485:2016 and takes effect February 2, 2026. Manufacturers must update design control and supplier records to match this standard before their next FDA inspection.
The program reduces Medicare inpatient payments by 1% for hospitals in the worst-performing quartile for conditions including surgical site infections. Hospitals therefore prioritize adhesive closures and dressings with documented infection-prevention performance.
Commerce's Section 232 investigation into medical devices and consumables, opened in September 2025, covers adhesive dressings and tapes. Importers should monitor the Bureau of Industry and Security determination, as tariffs would raise landed costs for imported acrylic and silicone inputs.
FDA's Center for Devices and Radiological Health enforces labeling requirements under 21 CFR Part 801 and unique device identification under 21 CFR Part 830. Non-compliance can result in misbranding findings and product holds at ports of entry.

Market Segmentation

By Product Type
  • Pressure-Sensitive Adhesives
  • Cyanoacrylate Tissue Adhesives
  • Fibrin Sealants
  • Hydrocolloid Adhesives
  • Silicone Adhesives
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Physician Offices
By Application
  • Wound Closure
  • Transdermal Drug Delivery
  • Ostomy and Wound Care
  • Device Assembly

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 United States Medical Adhesives - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 Pressure-Sensitive Adhesives
4.2 Cyanoacrylate Tissue Adhesives
4.3 Fibrin Sealants
4.4 Hydrocolloid Adhesives
4.5 Others
Chapter 05 End User Insights
5.1 Hospitals
5.2 Ambulatory Surgical Centers
5.3 Home Healthcare
5.4 Physician Offices
5.5 Others
Chapter 06 Application Insights
6.1 Wound Closure
6.2 Transdermal Drug Delivery
6.3 Ostomy and Wound Care
6.4 Device Assembly
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 3M
7.2.2 Johnson & Johnson
7.2.3 Avery Dennison Medical
7.2.4 H.B. Fuller
7.2.5 Henkel
7.2.6 Bostik
7.2.7 Smith & Nephew
7.2.8 Medline Industries
7.2.9 Cardinal Health
7.2.10 Tredegar Corporation
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.